We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.04% | 128.31 | 771 | 12:25:51 |
From May 2019 to May 2024
By Adria Calatayud
Shares in NetScientific PLC (NSCI.LN) rose Thursday after it said portfolio company PDS Biotechnology Corp. (PDSB) will collaborate with U.S. drug maker Merck & Co. Inc. (MRK) in a phase II clinical trial.
NetScientific, a London-based healthcare technology company, said the trial will study PDS's lead product, PDS0101, in combination with Merck's cancer drug Keytruda as a first line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection.
Shares in NetScientific at 1256 GMT were up 40% at 8.75 pence.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 03, 2019 09:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
